Cellphire, Inc. announced that Anne Hale, DVM has joined its veterinary subsidiary BodeVet, Inc. as its Chief Technical Officer. Dr. Hale is a renowned expert in veterinary transfusion medicine.
Dr. Hale has a strong academic track record and has received a NIH Comparative Fellowship in Transfusion Medicine. She founded and guided Midwest Animal Blood Services, an internationally known blood bank. Dr. Hale also worked as the CEO and Director for Animal Blood Resources International while the company launched a new line of lyophilized blood products. In addition, she held a position as an internist at the Veterinary Emergency and Specialist Centers in New Mexico before joining BodeVet.
Dr. Hale is a founding member of the American Association of Veterinary Blood Banks and is an active member of many other like organizations including the American Veterinary Medical Association, the North American Veterinary Regenerative Medicine Association, and the Association of Veterinary Hematology and Transfusion Medicine. She is also a trustee for The Pet Blood Bank UK.
“I look forward to helping BodeVet lead the way towards an evidence-based practice of transfusion medicine using the latest modified blood products,” said Dr. Hale. “Our lead product, StablePlate RX™, promises to profoundly influence bleeding management for both the veterinary trauma specialist and the general veterinary practitioner.”
BodeVet expects to commercially launch sales of StablePlate RX™ in September 2017.
“Dr. Hale is one of the nation’s top veterinary blood bankers,” said Cellphire CEO Stephen Willard. “We are very pleased to have her leading our efforts to save animal lives.”
About Cellphire
Cellphire, Inc. is a biotechnology company developing next-generation therapeutics. The company is applying its proprietary cell stabilization technology to all cell types, including platelets, to develop lifesaving products. Its lead product is Thrombosomes®, a freeze-dried hemostatic derived from human platelets. Cellphire’s technology has potential applications across a wide range of medical applications from trauma to wound care, imaging, targeted drug delivery, and regenerative medicine. For more information, visit www.cellphire.com.
Contacts:
Media
Sharon Burns
Director, Communications
sburns@cellphire.com
Investor Relations
Tom Dann
Chief Investment Officer
tdann@cellphire.com